bgb-11417
Small moleculeexperimental
Clinical trial activity
24 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
19
Phase 3
4
Phase 4
0
Earliest trial started Feb 28, 2020 (NCT04277637)
Timeline
Indications
Studied for
- Healthy Volunteers · Phase 1
- Leukemia · Phase 2
- Leukemia, B-Cell · Phase 1/Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 3
- Leukemia, Myeloid, Acute · Phase 2
- Lymphoma · Phase 2
- Lymphoma, B-Cell · Phase 3
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Mantle-Cell · Phase 3
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 2
- Medial Collateral Ligament, Knee · Phase 2
- Multiple Myeloma · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Myeloproliferative Disorders · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Waldenstrom Macroglobulinemia · Phase 2
Mechanism of action
- Apoptosis regulator Bcl-2INHIBITOR
BCL2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1- Mol. weight
- 890.12 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314951 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06859008 | Phase 1 | Feb 7, 2026 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT07277231 | Phase 3 | Jan 31, 2026 | BeOne Medicines |
| NCT06854003 | Phase 2 | Aug 31, 2025 | BeOne Medicines, Harvard University |
| NCT06849713 | Phase 2 | Jul 28, 2025 | BeOne Medicines, Harvard University |
| NCT06839053 | Phase 2 | Jul 1, 2025 | BeOne Medicines, University of Washington |
| NCT06943872 | Phase 3 | Jun 11, 2025 | BeOne Medicines, German CLL Study Group |
| NCT06742996 | Phase 3 | Jan 28, 2025 | BeOne Medicines |
| NCT06697184 | Phase 1/Phase 2 (Phase 2) | Dec 15, 2024 | BeOne Medicines |
| NCT06634589 | Phase 1/Phase 2 (Phase 2) | Dec 2, 2024 | BeOne Medicines |
| NCT06637501 | Phase 2 | Dec 1, 2024 | BeOne Medicines |
| NCT06547866 | Phase 2 | Oct 1, 2024 | BeOne Medicines, Centre Hospitalier le Mans, French Innovative Leukemia Organisation |
| NCT06497062 | Phase 2 | Sep 4, 2024 | BeOne Medicines, Jiao Tong University |
| NCT06463691 | Phase 2 | Aug 31, 2024 | Tianjin Medical University |
| NCT06543043 | Phase 1 | Aug 19, 2024 | BeOne Medicines, Quotient |
| NCT06367374 | Phase 2 | May 30, 2024 | China Academy of Chinese Medical Sciences |
| NCT06073821 | Phase 3 | Dec 1, 2023 | BeOne Medicines |
| NCT05952037 | Phase 2 | Sep 28, 2023 | BeOne Medicines |
| NCT05844111 | Phase 1 | May 22, 2023 | BeOne Medicines |
| NCT05479994 | Phase 2 | Oct 24, 2022 | BeOne Medicines |
| NCT05471843 | Phase 2 | Sep 5, 2022 | BeOne Medicines |
Showing 20 of 24 trials
Page 1 / 2
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BeOne Medicines | For profit | 21 | 16 | 3 | 2020 |
| Harvard University | Academic/Hospital | 2 | 2 | 1 | 2025 |
| Centre Hospitalier le Mans | Academic/Hospital | 1 | 0 | 1 | 2024 |
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2024 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2026 |
| French Innovative Leukemia Organisation | Academic/Hospital | 1 | 1 | 1 | 2024 |
| German CLL Study Group | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2026 |
| Quotient | For profit | 1 | 0 | 1 | 2024 |
| Tianjin Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2025 |
12 organizations
Page 1 / 1